Literature DB >> 3136426

[Corynebacterium group D2. Clinical study, biochemical identification and antibiotic sensitivity].

N Marty1, D Clave, B Cancet, S Henry-Ferry, J Didier.   

Abstract

The comparative study of 44 isolates of Corynebacterium group D2, from urine, most frequently, shows the pathogenic role of these bacteria in urinary tract infection, with or without urinary stones. These microorganisms have an opportunistic behaviour in other non-urinary sites, and become pathogen in immunosuppressed conditions. The rapid tests as urease, glucose acidification, nitrate reductase, associated with multiple resistance to antibiotics (beta-lactams and aminosides) identify easily Corynebacterium group D2, from 48 h cultures under CO2 conditions. The results of MIC determination of 10 antibiotics, show the high activity (100% sensitivity) of vancomycin and pristinamycin, with MIC modes, respectively, 0.5 and 0.03 mg/l. These antibiotics are the most useful for the treatment of non-urinary infections. Among quinolones, the most active agents are ciprofloxacin and ofloxacin (MIC modes: 4 and 2 mg/l), so these antimicrobials could be used for the treatment of urinary tract infections caused by Corynebacterium group D2.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3136426

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  10 in total

Review 1.  Coryneform bacteria in infectious diseases: clinical and laboratory aspects.

Authors:  M B Coyle; B A Lipsky
Journal:  Clin Microbiol Rev       Date:  1990-07       Impact factor: 26.132

2.  Increasing incidence of Corynebacterium group D2 strains resistant to norfloxacin and ciprofloxacin.

Authors:  F Soriano; R Fernández-Roblas; J Zapardiel; J L Rodríguez-Tudela; P Avilés; M Romero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

3.  In vitro susceptibility of Corynebacterium group D2 and Corynebacterium jeikeium to twelve antibiotics.

Authors:  A Philippon; F Bimet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

4.  In vitro activity of 79 antimicrobial agents against Corynebacterium group D2.

Authors:  J A García-Rodriguez; J E García Sánchez; J L Muñoz Bellido; T Nebreda Mayoral; E García Sánchez; I García García
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

5.  Adherence and hemagglutination of Corynebacterium group D2.

Authors:  N Marty; L Agueda; L Lapchine; D Clave; S Henry-Ferry; G Chabanon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-01       Impact factor: 3.267

Review 6.  Clinical microbiology of coryneform bacteria.

Authors:  G Funke; A von Graevenitz; J E Clarridge; K A Bernard
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

7.  Incidence and characteristics of urinary tract infections caused by Corynebacterium urealyticum (Corynebacterium group D2).

Authors:  T Nebreda-Mayoral; J L Muñoz-Bellido; J A Garcia-Rodríguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-07       Impact factor: 3.267

8.  Urinary tract infection with Corynebacterium urealyticum in South Africa.

Authors:  D Walkden; K P Klugman; S Vally; P Naidoo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-01       Impact factor: 3.267

Review 9.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

10.  Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin, and teicoplanin in an experimental model in rats.

Authors:  F Soriano; J L Rodriguez-Tudela; C Castilla; P Avilés
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.